Skip to content Skip to footer
Subscribe Now

INSIGHTS+

A Complete Account of EMA Approvals in 2023
A Complete Account of EMA Approvals in 2023
Shots:  In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology  For…
March 5, 2024
Insights+ Key Biosimilars Events of February 2024
Insights+ Key Biosimilars Events of February 2024
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During February, Sandoz received Health Canada’s approval for Jubbonti while Rani Therapeutics…
March 4, 2024
Know Your Investor (February Edition) F-Prime Capital Partners
Know Your Investor (February Edition): F-Prime Capital Partners
Shots:  Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry  Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare and technology  A total of 40 investments were closed by F-Prime in 2023,…
February 27, 2024
Top Performing Drug – Entyvio (February Edition)
Top Performing Drug – Entyvio (February Edition)
Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Entyvio and prepared a curated analysis report for our readers  Entyvio works on the mechanism of an integrin receptor antagonist, which is approved for moderate to severe active ulcerative colitis and active…
February 22, 2024
Insights+ EMA Marketing Authorization of New Drugs in January 2024
Insights+: EMA Marketing Authorization of New Drugs in January 2024
Shots: The EMA approved 2 BLA and 6 New Chemical Entities in January 2024, leading to treatments for patients and advances in the healthcare industry In January 2024, the major highlighted drugs were Padcev to treat Bladder Cancer and Eylea for the treatment of Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) PharmaShots has…
February 21, 2024
New Drug Designations - January 2024
New Drug Designations – January 2024
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EC, and China’s NMPA. This month’s report includes 13 small molecules, 7 devices, 3 biologics ADC, 3 gene therapy, 1 antineoplastics, 1 protein, 1 peptide, 1 recombinant enzyme & 1 vaccine   NRx Pharmaceuticals’ NRX-101 small molecule, focused…
February 20, 2024
Disease of the Month - Neuroblastoma
Disease of the Month – Neuroblastoma
Shots:  The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved   For the February edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Neuroblastoma, a rare…
February 13, 2024
Insights+: The US FDA New Drug Approvals in January 2024
Insights+: The US FDA New Drug Approvals in January 2024
Shots:  The US FDA approved 1 NDA in January 2024, leading to treatments for patients and advances in the healthcare industry  In January 2023, Zelsuvmi was approved by the US FDA for the Treatment of Molluscum Contagiosum  PharmaShots has compiled a list of US FDA-approved drugs in the month January 2024  1. Ligand Pharmaceuticals’ Zelsuvmi Receives…
February 8, 2024
Insights+ Key Biosimilars Events of January 2024
Insights+ Key Biosimilars Events of January 2024
Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During January, Coherus BioSciences divested its Ophthalmology Franchise that included Cimerli and Glenmark launched…
February 7, 2024
A Complete Account of FDA Approvals in 2023
A Complete Account of FDA Approvals in 2023
Shots:  2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023  PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology   For the complete report with analysis, reach out to us…
February 1, 2024
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]